Novo Nordisk's OASIS trial programme has tested oral Semaglutide at doses of 25mg and 50mg, producing weight loss results approaching those of the injectable 2.4mg formulation. This has significant implications for oral peptide research and delivery.
View the full PeptX research peptide catalogue, or browse Retatrutide, Tirzepatide, Semaglutide, BPC-157, TB-500 and GHK-Cu.